Skip Navigation



Annals of Oncology Advance Access published online on August 25, 2008
Annals of Oncology, doi:10.1093/annonc/mdn591
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/2/286    most recent
mdn591v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Oksefjell, H.
Right arrow Articles by Tropé, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oksefjell, H.
Right arrow Articles by Tropé, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer

H. Oksefjell1,*, B. Sandstad2 and C. Tropé1,3

1 Department of Gynaecological Oncology, The Norwegian Radium Hospital
2 Clinical Trials Unit, The Norwegian Radium Hospital and The Norwegian Cancer Association
3 University of Oslo, Oslo, Norway

* Correspondence to: H. Oksefjell MD, Department of Gynaecological Oncology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway. Tel: +47 22934000, Fax: +47 22934469; E-mail: halldis.oksefjell{at}radiumhospitalet.no

Background: The aim of this study was to investigate the benefit of secondary cytoreduction (SCR) in the first relapse in epithelial ovarian cancer and to attempt to define selection criteria for SCR.

Patients and methods: A retrospective population-based study on recorded information from 789 patients treated at the Norwegian Radium Hospital during 1985–2000 for their initial recurrence. In all, 217 had SCR and 572 were treated with chemotherapy alone.

Results: Median survival time (MST) was 1.1 years for the chemotherapy group. Complete optimal cytoreduction (COC) was achieved in 35% of all 217 patients, in 49% of the patients operated with debulking intent and in 52% if bowel surgery was done with debulking intent. MST was 4.5 versus 0.7 years for 0 versus>2 cm residual disease, respectively. Residual disease after SCR, treatment-free interval (TFI) and age were found to be prognostic factors for overall survival (OS) in multivariate analysis. Localised tumour was found to be the only significant factor to predict COC.

Conclusions: SCR followed by chemotherapy gives a clear survival benefit compared with chemotherapy and should be offered when the tumour is localised. The combination of COC, TFI >24 months and age ≤39 years identifies a group of patients with the best OS.

first relapse, ovarian cancer, secondary cytoreduction

Received for publication May 28, 2008. Revision received July 24, 2008. Accepted for publication July 25, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am Soc Clin Oncol Ed BookHome page
D. Yamada
The Role of Surgery in Ovarian Cancer Management
ASCO Educational Book, January 1, 2009; 2009(1): 302 - 307.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.